ClinicalTrials.gg
RecruitingNCT05907239Updated Mar 25, 2026

Effects of Focal Extracorporeal Shock Wave Therapy in the Treatment of Temporomandibular Disorders of Muscular Origin

An interventional study of Focused Extracorporeal Shockwave Therapy and Placebo Focused Extracorporeal Shockwave Therapy in Temporomandibular Joint Disorders and Extracorporeal Shockwave Therapy, sponsored by University of Sao Paulo General Hospital. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Temporomandibular Joint Disorders with a site in Brazil — 7 open to participants now, 7 under way, none of them phase 3. Temporomandibular Joint Disorders · Brazil.

Planned enrollment
5th of 36
100 · median 40
Started
2023
with 4 others
No phase
28 of 44
5 open now
Registered
40th of 44
by date
Lead sponsor
3 of 44
University of Sao Paulo General Hospital

Among the 44 studies in Temporomandibular Joint Disorders with a site in Brazil, this one is the 5th largest by planned enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2023, is one of 28 with no phase, and was the 40th registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

7 of the 44 studies in Temporomandibular Joint Disorders with a site in Brazil are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Temporomandibular Joint Disorders with a site in Brazil, or all of them as a file.
02

Study summary

The objective of the study is to evaluate the effectiveness of extracorporeal shock wave therapy (ESWT) in improving pain in patients with TMD pain after 5 weeks of treatment, 1 month and 3 months after the end of treatment. As secondary objectives, we plan to evaluate the effectiveness of focal shockwave therapy in relation to:

  1. Range of motion (ROM) of the temporomandibular joint using goniometry after 5 weeks of treatment;
  2. Degree of inflammation, using ultrasound evaluation in the temporomandibular joint relating to the degree of pain after focal shockwave therapy for 5 weeks;
  3. Jaw movement (MM), joint noise (RA), joint pressure (PA) and disability index (DI) will be measured at each treatment session and after 5 weeks of treatment, 1 month and 3 months after the end of treatment in the affected joints;
  4. Quality of life will be assessed using the "Short Form Health 36" questionnaire (SF-36) during the 5 weeks of treatment, 1 month and 3 months after the end of treatment;
  5. Pain control medication will also be considered and compared before and after the proposed treatment for 5 weeks.

Safety will be assessed throughout the study by monitoring the incidence of study-related adverse events. All patients will be contacted periodically and encouraged to report any side effects.

Read the detailed description

Introduction: Temporomandibular disorders (TMDs) are clinical conditions that affect the masticatory muscles, the temporomandibular joint (TMJ) and associated structures. Focal extracorporeal shock wave therapy (ESWT) can be used for the treatment of musculoskeletal disorders with good results in the literature and with the potential to treat muscular TMDs.

Objective: The aim of the study is to perform a double-blind randomized controlled clinical trial to evaluate the effects of focal shock wave therapy in the treatment of pain due to temporomandibular disorders of muscular origin in adults after 5 weeks of treatment, 1 and 3 months after the end of treatment.

Methods: A double-blind randomized controlled clinical trial will be carried out with 50 patients in the control group and 50 patients in the intervention group. Patients will be prospectively selected at the Orofacial Pain Outpatient Clinic of the Division of Dentistry, Instituto Central, Hospital das Clínicas, Faculty of Medicine, University of São Paulo (IC-HCFMUSP) and will be referred to the Acupuncture Center of the Institute of Orthopedics and Traumatology of HCFMUSP (IOT-HCFMUSP). The control group will initially undergo treatment with guidelines for muscular temporomandibular disorders and treatment by shockwave therapy with a "placebo" applicator for 5 weeks, while the intervention group will undergo the same guidelines and treatment by shockwave therapy. focal point on the masticatory muscles during 5 sessions, once a week (totaling 5 weeks). After the initial treatment period, the groups will be evaluated and compared in terms of improvement in pain and quality of life, in addition to follow-up after 1 month, 3 months and 6 months after the procedure.

Expected results: After the standardized treatment period of 1 weekly session in 5 consecutive weeks (totalizing 5 sessions), it is expected that there will be an improvement in the pain Visual Analogue Scale (VAS) and in the quality of life of patients with muscular TMDs. As there is a stimulus for differentiation of mesenchymal stem cells, neovascularization and release of angiogenic factors to occur, the effect of ESWT is expected to be lasting throughout the reassessments at 1 and 3 months.

Keywords: Temporomandibular Joint Disorders, Extracorporeal Shockwave Therapy, Temporomandibular Joint Dysfunction Syndrome, High-Energy Shock Waves, Pain Management

03

Conditions studied

  • Temporomandibular Joint Disorders
  • Extracorporeal Shockwave Therapy

Keywords

  • Temporomandibular Joint Disorders
  • Extracorporeal Shockwave Therapy
  • Temporomandibular Joint Dysfunction Syndrome
  • High-Energy Shock Waves
  • Pain Management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pain in the temporomandibular region;
  • Myofascial pain diagnosed with or without limitation of mouth opening based on the Diagnostic Criteria for TMD (DC/TMD);
  • Myofascial pain associated or not with joint abnormalities;
  • Presence of moderate to severe pain: Visual Analogue Scale (VAS) >4;
  • Duration of TMD pain (temporomandibular musculoskeletal) ≥3 months;
  • Written granting of the form to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Abnormality in blood clotting (coagulopathy) or using some type of anticoagulant;
  • Primary malignant disease (tumors) in the treatment area;
  • Acute infection of soft tissue or bone;
  • Systemic infections;
  • Epilepsy;
  • Infiltration of at the application site in the last 6 weeks;
  • Patient at high risk of some type of anesthesia or analgesia when it eventually has to be used;
  • Polyarthritis;
  • Polytrauma Local joint infections;
  • Previous temporomandibular surgical treatments that compromise mastication;
  • Treatment by physiotherapy, acupuncture before 3 months of performing the procedures
  • Depression or other mental disorders;
  • Clinical diagnosis of associated fibromyalgia;
  • Associated systemic inflammatory rheumatic diseases;
  • Widespread pain or pain elsewhere that predominates and overlaps with TMD muscle pain;
  • Inability to understand the treatment protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Treatment group will undergo treatment with focal shock wave therapy for 5 weeks, with weekly sessions and guidance by a trained physiotherapist on habits, stretching and exercises for adequate strengthening and ergonomic guidelines to promote a better quality of life

    Device: Focused Extracorporeal Shockwave Therapy

  • Placebo comparator
    Placebo

    Patients in the placebo group will undergo treatment with placebo focal shockwave therapy (using a dummy applicator) for 5 weeks and guidance by a trained physiotherapist on habits, stretching and exercises for adequate strengthening and ergonomic guidelines to promote a better quality of life

    Device: Placebo Focused Extracorporeal Shockwave Therapy

Interventions

  • DeviceFocused Extracorporeal Shockwave Therapy

    We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 1.5cm in depth, frequency of 8Hz and intensity of 0.048mJ/mm² as long as it is tolerable to the patient (it can be reduced to a tolerable intensity of at least 0.018mJ/mm²) starting with a density of energy flow between 0.12 to 0.15 mJ/mm2, starting from an adaptation dose of 0.10 mJ/mm2 in the first 500 impulses. The non-stationary technique will be used, slowly moving the applicator. Shockwave therapy will be weekly, totaling five consecutive weeks.

  • DevicePlacebo Focused Extracorporeal Shockwave Therapy

    We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 0cm depth, frequency of 8Hz and intensity of 0.048mJ/mm² with a fake gel pad applicator.

06

What researchers measure

Primary outcomes

  1. Pain Visual Analogue Scale ("VAS")

    Change of pain perception after application of focal shock wave therapy ranging from 0 (painless) to 10 (painful)

    Time frame: 3 months

Secondary outcomes

  1. Pressure pain threshold

    Test that uses an algometer in order to define the minimum pressure that triggers pain, at pre-established points (temporomandibular region).

    Time frame: 3 months

  2. Range of Motion

    Change of range of motion (ROM) of the temporomandibular joint using ruler

    Time frame: 3 months

  3. Quality of life assessed by the "Short Form Health 36" questionnaire (SF-36)

    Quality of life will be assessed by the "Short Form Health 36" questionnaire (SF-36) ranging from 0 to 100

    Time frame: 3 months

  4. Mandibular movement and joint noise

    Mandibular movement (MM) and joint noise (JN) will be assessed by a trained physiotherapist. The opening pattern will be evaluated through the vertical extension of mandibular movement; maximum opening without assistance; maximum opening with assistance; "overbit". Mandibular movements will be evaluated for right and left lateral excursion, in addition to referred pain in movement. Protrusions and deviations from the midline will also be evaluated.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Asquini G, Pitance L, Michelotti A, Falla D. Effectiveness of manual therapy applied to craniomandibular structures in temporomandibular disorders: A systematic review. J Oral Rehabil. 2022 Apr;49(4):442-455. doi: 10.1111/joor.13299. Epub 2022 Jan 17. PubMed 34931336 ↗
  • Chung J, Lobbezoo F, van Selms MKA, Chattrattrai T, Aarab G, Mitrirattanakul S. Physical, psychological and socio-demographic predictors related to patients' self-belief of their temporomandibular disorders' aetiology. J Oral Rehabil. 2021 Feb;48(2):109-123. doi: 10.1111/joor.13113. Epub 2020 Oct 26. PubMed 33051894 ↗
  • Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, List T, Svensson P, Gonzalez Y, Lobbezoo F, Michelotti A, Brooks SL, Ceusters W, Drangsholt M, Ettlin D, Gaul C, Goldberg LJ, Haythornthwaite JA, Hollender L, Jensen R, John MT, De Laat A, de Leeuw R, Maixner W, van der Meulen M, Murray GM, Nixdorf DR, Palla S, Petersson A, Pionchon P, Smith B, Visscher CM, Zakrzewska J, Dworkin SF; International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Groupdagger. J Oral Facial Pain Headache. 2014 Winter;28(1):6-27. doi: 10.11607/jop.1151. PubMed 24482784 ↗
  • Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dent Assoc. 1993 Oct;124(10):115-21. doi: 10.14219/jada.archive.1993.0200. No abstract available. PubMed 8409001 ↗
  • Skarmeta NP, Pesce MC, Saldivia J, Espinoza-Mellado P, Montini F, Sotomayor C. Changes in understanding of painful temporomandibular disorders: the history of a transformation. Quintessence Int. 2019;50(8):662-669. doi: 10.3290/j.qi.a42779. PubMed 31286120 ↗
  • Medlicott MS, Harris SR. A systematic review of the effectiveness of exercise, manual therapy, electrotherapy, relaxation training, and biofeedback in the management of temporomandibular disorder. Phys Ther. 2006 Jul;86(7):955-73. PubMed 16813476 ↗
  • Shimada A, Ishigaki S, Matsuka Y, Komiyama O, Torisu T, Oono Y, Sato H, Naganawa T, Mine A, Yamazaki Y, Okura K, Sakuma Y, Sasaki K. Effects of exercise therapy on painful temporomandibular disorders. J Oral Rehabil. 2019 May;46(5):475-481. doi: 10.1111/joor.12770. Epub 2019 Feb 19. PubMed 30664815 ↗
  • Arber W, Kuhnlein U. [Mutational loss of the B-specific restriction in bacteriophage fd]. Pathol Microbiol (Basel). 1967;30(6):946-52. No abstract available. German. PubMed 4873409 ↗
  • Vervaeke K, Verhelst PJ, Orhan K, Lund B, Benchimol D, Van der Cruyssen F, De Laat A, Jacobs R, Politis C. Correlation of MRI and arthroscopic findings with clinical outcome in temporomandibular joint disorders: a retrospective cohort study. Head Face Med. 2022 Jan 7;18(1):2. doi: 10.1186/s13005-021-00305-y. PubMed 34996509 ↗
  • Li W, Wu J. Treatment of Temporomandibular Joint Disorders by Ultrashort Wave and Extracorporeal Shock Wave: A Comparative Study. Med Sci Monit. 2020 Jun 21;26:e923461. doi: 10.12659/MSM.923461. PubMed 32564051 ↗
  • Jiao K, Niu LN, Wang MQ, Dai J, Yu SB, Liu XD, Wang J. Subchondral bone loss following orthodontically induced cartilage degradation in the mandibular condyles of rats. Bone. 2011 Feb;48(2):362-71. doi: 10.1016/j.bone.2010.09.010. Epub 2010 Sep 17. PubMed 20850574 ↗
  • Ioppolo F, Rompe JD, Furia JP, Cacchio A. Clinical application of shock wave therapy (SWT) in musculoskeletal disorders. Eur J Phys Rehabil Med. 2014 Apr;50(2):217-30. Epub 2014 Mar 26. PubMed 24667365 ↗
  • Imamura M, Alamino S, Hsing WT, Alfieri FM, Schmitz C, Battistella LR. Radial extracorporeal shock wave therapy for disabling pain due to severe primary knee osteoarthritis. J Rehabil Med. 2017 Jan 19;49(1):54-62. doi: 10.2340/16501977-2148. PubMed 27904912 ↗
  • Iuamoto LR, Imamura M, Sameshima K, Meyer A, Simis M, Battistella LR, Fregni F. Functional Changes in Cortical Activity of Patients Submitted to Knee Osteoarthritis Treatment: An Exploratory Pilot Study. Am J Phys Med Rehabil. 2022 Oct 1;101(10):920-930. doi: 10.1097/PHM.0000000000001931. Epub 2021 Nov 18. PubMed 34799508 ↗
  • Santamato A, Beatrice R, Micello MF, Fortunato F, Panza F, Bristogiannis C, Cleopazzo E, Macarini L, Picelli A, Baricich A, Ranieri M. Power Doppler Ultrasound Findings before and after Focused Extracorporeal Shock Wave Therapy for Achilles Tendinopathy: A Pilot Study on Pain Reduction and Neovascularization Effect. Ultrasound Med Biol. 2019 May;45(5):1316-1323. doi: 10.1016/j.ultrasmedbio.2018.12.009. Epub 2019 Feb 8. PubMed 30739723 ↗
  • Moya D, Ramon S, Schaden W, Wang CJ, Guiloff L, Cheng JH. The Role of Extracorporeal Shockwave Treatment in Musculoskeletal Disorders. J Bone Joint Surg Am. 2018 Feb 7;100(3):251-263. doi: 10.2106/JBJS.17.00661. No abstract available. PubMed 29406349 ↗
  • Holfeld J, Tepekoylu C, Kozaryn R, Urbschat A, Zacharowski K, Grimm M, Paulus P. Shockwave therapy differentially stimulates endothelial cells: implications on the control of inflammation via toll-Like receptor 3. Inflammation. 2014 Feb;37(1):65-70. doi: 10.1007/s10753-013-9712-1. PubMed 23948864 ↗
  • Kuo YR, Wang CT, Wang FS, Chiang YC, Wang CJ. Extracorporeal shock-wave therapy enhanced wound healing via increasing topical blood perfusion and tissue regeneration in a rat model of STZ-induced diabetes. Wound Repair Regen. 2009 Jul-Aug;17(4):522-30. doi: 10.1111/j.1524-475X.2009.00504.x. PubMed 19614917 ↗
  • Kim YH, Bang JI, Son HJ, Kim Y, Kim JH, Bae H, Han SJ, Yoon HJ, Kim BS. Protective effects of extracorporeal shockwave on rat chondrocytes and temporomandibular joint osteoarthritis; preclinical evaluation with in vivo99mTc-HDP SPECT and ex vivo micro-CT. Osteoarthritis Cartilage. 2019 Nov;27(11):1692-1701. doi: 10.1016/j.joca.2019.07.008. Epub 2019 Jul 16. PubMed 31323297 ↗
  • Mattyasovszky SG, Langendorf EK, Ritz U, Schmitz C, Schmidtmann I, Nowak TE, Wagner D, Hofmann A, Rommens PM, Drees P. Exposure to radial extracorporeal shock waves modulates viability and gene expression of human skeletal muscle cells: a controlled in vitro study. J Orthop Surg Res. 2018 Apr 6;13(1):75. doi: 10.1186/s13018-018-0779-0. PubMed 29625618 ↗
  • Gupta B, Ahmed N, Sidebottom AJ. Quality of life outcomes one year after replacement of the temporomandibular joint using a modified SF36 questionnaire. Br J Oral Maxillofac Surg. 2020 Apr;58(3):304-308. doi: 10.1016/j.bjoms.2019.12.003. Epub 2020 Mar 5. PubMed 32147223 ↗
  • Dib-Zakkour J, Flores-Fraile J, Montero-Martin J, Dib-Zakkour S, Dib-Zaitun I. Evaluation of the Effectiveness of Dry Needling in the Treatment of Myogenous Temporomandibular Joint Disorders. Medicina (Kaunas). 2022 Feb 9;58(2):256. doi: 10.3390/medicina58020256. PubMed 35208580 ↗
  • Schmitz C, Csaszar NB, Milz S, Schieker M, Maffulli N, Rompe JD, Furia JP. Efficacy and safety of extracorporeal shock wave therapy for orthopedic conditions: a systematic review on studies listed in the PEDro database. Br Med Bull. 2015;116(1):115-38. doi: 10.1093/bmb/ldv047. Epub 2015 Nov 18. PubMed 26585999 ↗
  • Rompe JD, Meurer A, Nafe B, Hofmann A, Gerdesmeyer L. Repetitive low-energy shock wave application without local anesthesia is more efficient than repetitive low-energy shock wave application with local anesthesia in the treatment of chronic plantar fasciitis. J Orthop Res. 2005 Jul;23(4):931-41. doi: 10.1016/j.orthres.2004.09.003. PubMed 16023010 ↗
  • Alessandri-Bonetti G, Bortolotti F, Bartolucci ML, Marini I, D'Anto V, Michelotti A. The Effects of Mandibular Advancement Device on Pressure Pain Threshold of Masticatory Muscles: A Prospective Controlled Cohort Study. J Oral Facial Pain Headache. 2016 Summer;30(3):234-40. doi: 10.11607/ofph.1500. PubMed 27472526 ↗

Individual participant data

Plan to share: No — Only Study Protocol will be shared and other details of the study (Statistical analysis plan, clinical study report) at the end of recruiting phase.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Nov 2027, 54 months after the start.

Of 244 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 54 months is above that.

Counting every sponsor, half of 248 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jun 18, 2023
StartActual
Apr 20, 2023
Primary completionEst.
Nov 3, 2027
CompletionEst.
Jun 25, 2029
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05907239
Responsible party
Wu Tu Hsing (Director of Center of Acupuncture of Institute of Orthopaedics and Traumatology, University of Sao Paulo General Hospital) — Principal investigator
First posted
Jun 18, 2023
Start date
Apr 20, 2023
Primary completion
Nov 3, 2027 (estimated)
Completion
Jun 25, 2029 (estimated)
Last update
Mar 25, 2026

Study contacts

Wu T Hsing, MD, PhD
Contact
wu@fm.usp.br
+5511981998157
Leandro R Iuamoto, MD
Contact
leandro.iuamoto@fm.usp.br
Wu T Hsing, MD, PhD
principal investigator · University of Sao Paulo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion